Nova Eye Medical (ASX:EYE): How iTrack Advance Supports Canaloplasty in Glaucoma Care

Aditi Sarkar

14 October 2026 08:18 PM AEDT

Nova Eye Medical (ASX:EYE): How iTrack Advance Supports Canaloplasty in Glaucoma Care

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Nova Eye Medical develops ophthalmic devices for glaucoma treatment, including the iTrack family of microcatheters.
iTrack Advance is designed for 360-degree catheterisation and viscodilation of the eye’s conventional drainage pathway.
The company’s January 2026 registry update reported outcomes from eyes followed for 12 months.
Nova Eye announced EU Medical Device Regulation certification in March 2026.
Its 2026 company communications include product updates and FY26 financial reporting.

Nova Eye Medical Limited (ASX:EYE) develops and commercialises ophthalmic technologies, with a focus on surgical devices for glaucoma. Its iTrack microcatheter platform supports canaloplasty, a procedure intended to improve fluid drainage within the eye. During 2026, the company reported clinical registry findings, a European regulatory development and ongoing commercial activity relating to its glaucoma products.

How 360-Degree Canaloplasty Works

Glaucoma treatment often seeks to reduce intraocular pressure, an important factor in managing the condition. Canaloplasty addresses the eye’s conventional drainage system rather than introducing an implanted bypass. Nova Eye Medical (ASX:EYE) describes its approach as 360-degree catheterisation and pressurised viscodilation of Schlemm’s canal and the associated outflow pathway.

The iTrack Advance device uses an illuminated microcatheter to help the surgeon navigate the canal. Viscodilation is intended to address resistance across the trabecular meshwork, Schlemm’s canal and collector channels. The procedure’s design is distinct from techniques that cut through the trabecular meshwork; individual outcomes nonetheless depend on clinical circumstances and surgical assessment.

Clinical Registry Evidence Reported in 2026

On 27 January 2026, Nova Eye Medical (ASX:EYE) released an update from the iTrack Global Data Registry. The company reported an 85% success rate among 409 eyes followed for 12 months where baseline intraocular pressure exceeded 18 mmHg. It also reported minimal complications across more than 600 eyes recorded in the registry.

The registry collects cases contributed by surgeons and provides information on device use in clinical practice. Its reported findings describe observed outcomes in the specified patient group; they should not be interpreted as a guarantee of success for every patient. The scope, follow-up period and starting intraocular pressure are important when interpreting the reported percentage.

Regulatory and Commercial Developments

Nova Eye Medical (ASX:EYE) announced EU Medical Device Regulation certification on 3 March 2026. Such certification is relevant to the regulatory framework governing medical-device access in European markets, although local availability, surgeon adoption and sales outcomes remain separate considerations.

The company also published a May 2026 update titled “Record April Sales Drive FY26 Guidance Upgrade” and released its annual financial reporting in August 2026. These disclosures address the company’s commercial operations and reported financial performance during FY26. The financial statements remain the appropriate basis for assessing sales, operating expenditure and cash movements.

Operating Considerations for a Medical-Device Business

For Nova Eye Medical (ASX:EYE), clinical evidence and regulatory approvals serve different functions. Registry observations inform understanding of patient outcomes, while device certifications address applicable market requirements. Neither alone establishes the pace of adoption by ophthalmic surgeons or the resulting financial performance.

Medical-device commercialisation also involves manufacturing consistency, clinician training, market access and competitive offerings. In glaucoma procedures, reimbursement arrangements and regional healthcare systems may affect how devices are used. These factors provide context for evaluating future operational disclosures without implying a particular commercial result.

Key Insights

Nova Eye Medical (ASX:EYE) combines a 360-degree canaloplasty device platform with clinical data collection and regulatory activity. Its January 2026 registry update provides a defined patient-outcome measure, while the March certification adds a separate regulatory milestone. The distinction between clinical findings, market authorisation and realised commercial performance remains central to understanding the business.

FAQs

Q:What does Nova Eye Medical develop?

A:It develops ophthalmic technologies, including microcatheter systems for glaucoma procedures.

Q:What is iTrack Advance used for?

A:It supports catheter-based canaloplasty and viscodilation of the eye’s conventional fluid outflow pathway.

Q:What did the January 2026 registry update report?

A:The company reported 85% success among 409 qualifying eyes followed for 12 months.

Q:What regulatory development occurred in March 2026?

A:The company announced EU Medical Device Regulation certification.

Q:Do registry results establish outcomes for every patient?

A:No. The reported outcomes apply to the specified registry group and follow-up period.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.